An indication with the corporate logo outside the headquarters of Eli Lilly and Company in Indianapolis, Indiana, March 17, 2024.
Scott Olson | Getty Images
A version of this text first appeared in CNBC’s Healthy Returns newsletter, which brings the most recent health-care news straight to your inbox. Subscribe here to receive future editions.
Earlier this month, Berkshire Hathaway topped $1 trillion in market value, the primary non-tech company within the U.S. to accomplish that. Soon, pharmaceutical giant Eli Lilly could change into the primary health-care company to hitch that club.Â
Why? Eli Lilly is riding the soaring demand for its injectable weight reduction drug Zepbound and diabetes medication Mounjaro, that are incretin drugs that mimic hormones produced within the gut to tamp down appetite and regulate blood sugar. Revenue from Mounjaro and Zepbound now account for nearly 40% of Eli Lilly’s total sales, in response to its second-quarter leads to August. Â
The corporate is one in every of two dominant players in the burden loss drug market, which some analysts imagine may very well be price $150 billion by the tip of the last decade. Eli Lilly may be pulling ahead of its fundamental rival, Novo Nordisk, because it shows progress toward expanding the provision of its drugs.Â
Novo Nordisk can be investing billions to spice up manufacturing. But its own weight reduction and diabetes drugs, Wegovy and Ozempic, missed sales expectations for the second quarter partially as a consequence of pricing pressure within the U.S.Â
Investors are also encouraged by the opposite possible health advantages of Eli Lilly’s treatments, which could boost their long-term revenue potential. The corporate has released several study results over the past yr showing Zepbound’s promise as a treatment for obesity-related conditions comparable to obstructive sleep apnea, fatty liver disease and heart problems.Â
Shares of Eli Lily have soared greater than 60% this yr, putting its market value at nearly $900 billion.Â
And the corporate could reach that $1 trillion mark soon. Eli Lilly’s stock soared almost 10% on Aug. 8 following its second-quarter results that surpassed Wall Street’s expectations. The drugmaker could post one other blowout quarter on Oct. 30.Â
Shares could also get a lift from potential data and regulatory approvals. For instance, Eli Lilly expects the Food and Drug Administration to make a choice on whether to approve Zepbound for sleep apnea by the tip of the yr.Â
Eli Lilly could potentially release data from a late-stage trial that pits Zepbound directly against Novo Nordisk’s Wegovy by the tip of the yr, in response to an Aug. 20 note from Leerink Partners analyst David Risinger.Â
Be at liberty to send any suggestions, suggestions, story ideas and data to Annika at annikakim.constantino@nbcuni.com.
Latest in health-care tech: One other continuous glucose monitor hits the market
Stacey Wescott | Chicago Tribune | Tribune News Service | Getty Images
It’s raining continuous glucose monitors!Â
Abbott Laboratories on Thursday announced its first over-the-counter continuous glucose monitor Lingo is obtainable within the U.S., just days after its competitor Dexcom launched an analogous product.
Continuous glucose monitors are small sensors that stick through the skin to measure real-time glucose levels. The devices have traditionally been prescribed to diabetes patients since they will help alert those users to emergencies. Lingo is more consumer friendly, because it’s meant for adults who will not be taking insulin.Â
Glucose is a sugar molecule that comes from food, and it is the body’s fundamental source of energy. Everyone’s glucose levels fluctuate, but consistently elevated levels can result in more serious conditions like heart disease, insulin resistance and metabolic disease, Abbott said.
Lingo is designed to assist users find out about how their bodies reply to food, exercise, sleep and stress, in addition to how they will manage their glucose levels in healthier ways.Â
The U.S. Food and Drug Administration approved Lingo in June. It’s available with out a prescription, and users should buy one sensor online for $49, two sensors for $89 or six sensors for $249.
Dexcom’s latest over-the-counter continuous glucose monitor is named Stelo, and the FDA approved it in March. An ongoing Stelo subscription costs $89 a month, and users may also buy a one-month supply for $99 at a time.
I tested out Stelo prior to its launch, and you’ll be able to examine my experience here. I have never tried Lingo yet, but Abbott walked me through the app and the way it really works.Â
One feature that stood out to me is Abbott’s “Lingo Count,” a metric designed to assist users understand glucose spikes. That happens when the quantity of sugar present within the bloodstream rapidly increases after which decreases, commonly after eating.Â
The Lingo Count algorithm assigns a numeric value to every glucose spike, and it’s presupposed to represent how significant the impact of that fluctuation is. Users have a complete goal Lingo Count that they wish to aim to remain below every day, they usually can see their progress over time.Â
With a purpose to learn find out how to manage glucose spikes, Lingo users can take part in challenges and access educational materials throughout the app. I believe the challenges could function a fun method to engage people around their glucose, and I’m interested to try them for myself.Â
On the entire, I believed the app seemed intuitive and helpful. The information is presented in a way that does not feel too complex or overwhelming, and consumers have the choice to go deeper in the event that they want. Â
I’m planning to check out Lingo later this month, so I’ll have more to share soon!
Be at liberty to send any suggestions, suggestions, story ideas and data to Ashley at ashley.capoot@nbcuni.com.
